NCT05210504View on ClinicalTrials.gov

Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

January 27, 2023

Study Completion Date

January 27, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

L-Lysine

5g L-lysine in 50ml water, administered orally

DRUG

Normal Saline

Normal (0.9%) Saline

Trial Locations (1)

37212

Vanderbilt University Medical Center, Nashville

All Listed Sponsors
lead

Vanderbilt University Medical Center

OTHER

NCT05210504 - Determinants of Alpha-aminoadipic Acid (2-AAA) and Relationship to Diabetes: Study 3 | Biotech Hunter | Biotech Hunter